Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 582
- Registration Number
- NCT04438837
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 500
- Registration Number
- NCT04437693
Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 1
- Registration Number
- NCT04435808
- Locations
- 🇺🇸
University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- WellStar Health System
- Target Recruit Count
- 700
- Registration Number
- NCT04429867
- Locations
- 🇺🇸
Wellstar Kennestone Hospital, Marietta, Georgia, United States
Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 70
- Registration Number
- NCT04421664
- Locations
- 🇨🇦
McMaster University, Hamilton, Ontario, Canada
🇨🇦Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada
🇨🇦University of Manitoba, Winnipeg, Manitoba, Canada
Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2021-05-12
- Target Recruit Count
- 142
- Registration Number
- NCT04420247
- Locations
- 🇧🇷
Centro de Estudos e Pesquisa em Emergencias Clinicas e Terapia Intensiva, Curitiba, Parana, Brazil
Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Universidad Peruana Cayetano Heredia
- Target Recruit Count
- 68
- Registration Number
- NCT04414241
- Locations
- 🇵🇪
Centro Médico Naval "Cirujano Mayor Santiago Távara", Callao, Peru
🇵🇪Hospital Nacional Arzobispo Loayza, Lima, Peru
🇵🇪Hospital Cayetano Heredia, Lima, Peru
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Ministry of Health, Turkey
- Target Recruit Count
- 1008
- Registration Number
- NCT04411433
- Locations
- 🇹🇷
Hacettepe University, School of Medicine, Ankara, Turkey
Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Barcelona Institute for Global Health
- Target Recruit Count
- 129
- Registration Number
- NCT04410562
- Locations
- 🇪🇸
Hospital General de Segovia, Segovia, Cartilla Y León, Spain
🇪🇸Hospital del Mar, Barcelona, Catalunya, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Catalunya, Spain
COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 336
- Registration Number
- NCT04397328
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.